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Introduction
Demyelination of  the axons of  CNS neurons can result from a wide range of  insults, including metabolic 
disturbances, certain viral infections, physical injury, and chronic inflammatory diseases, particularly mul-
tiple sclerosis (MS). It is inevitably accompanied by the death of  mature oligodendrocytes (OLG) and 
axonal damage. In counterbalance, the CNS quickly responds to demyelination by the activation of  endog-
enous repair responses that share mechanisms of  neuroinflammation, remyelination, and neuroprotection, 
and therefore represent important common targets for therapeutic intervention in a wide range of  patholo-
gies (1). In MS, the risk of  disease development is determined partly by genetic factors relating to immune 
system activation (2, 3). In early disease, treatments that modulate immune function, particularly T and 
B cell responses, are effective at reducing disease relapses and preserving CNS structure and function (4). 
However, much less is known about how demyelination continues to expand and why remyelination largely 
fails in later progressive forms of  MS (5, 6), where immune system involvement is reduced, blood-brain bar-
rier (BBB) function is at least partially recovered, and current antiinflammatory and immunosuppressive 
therapies are ineffective (7).
Remyelination is an inherent regenerative process of  the adult CNS that is triggered in response to 
myelin damage (8). It is mediated by OLG progenitor cells (OPC) that migrate toward environmental 
cues, proliferate, and differentiate to synthesize new myelin sheaths around demyelinated axons (8). In 
progressive MS, areas of  slowly expanding demyelination correlate with areas of  remyelination, indicating 
that demyelination occurs repeatedly at the same CNS locations, thereby exposing axons to continuous 
injury (5). These data suggest that the mechanisms regulating demyelination and remyelination might be 
Multiple sclerosis (MS) is an inflammatory CNS demyelinating disease in which remyelination 
largely fails. Transmembrane TNF (tmTNF) and TNF receptor 2 are important for remyelination 
in experimental MS models, but it is unknown whether soluble TNF (solTNF), a major 
proinflammatory factor, is involved in regeneration processes. Here, we investigated the specific 
contribution of solTNF to demyelination and remyelination in the cuprizone model. Treatment 
with XPro1595, a selective inhibitor of solTNF that crosses the intact blood-brain barrier (BBB), 
in cuprizone-fed mice did not prevent toxin-induced oligodendrocyte loss and demyelination, 
but it permitted profound early remyelination due to improved phagocytosis of myelin debris 
by CNS macrophages and prevented disease-associated decline in motor performance. The 
beneficial effects of XPro1595 were absent in TNF-deficient mice and replicated in tmTNF-knockin 
mice, showing that tmTNF is sufficient for the maintenance of myelin and neuroprotection. 
These findings demonstrate that solTNF inhibits remyelination and repair in a cuprizone 
demyelination model and suggest that local production of solTNF in the CNS might be one reason 
why remyelination fails in MS. These findings also suggest that disinhibition of remyelination 
by selective inhibitors of solTNF that cross the BBB might represent a promising approach for 
treatment in progressive MS.
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intricately linked. An understanding of  why remyelination fails in MS, and the identification of  mediators 
that promote or inhibit remyelination, are important for the development of  neuroprotective strategies 
for the treatment of  progressive MS. One potential approach is modulation of  the inflammatory environ-
ment in demyelinating lesions to favor remyelination, although cellular and molecular mechanisms that 
are specifically involved in the remyelination process need to be elucidated. Inflammation plays a dual role 
in CNS demyelination; chronic inflammation promotes degeneration, while acute inflammation favors 
remyelination (9). As an example, blood-derived macrophages are mainly responsible for autoimmune 
demyelination in experimental autoimmune encephalomyelitis (EAE) (10, 11) but facilitate remyelination 
via phagocytosis of  myelin debris and clearance of  myelin inhibitors in a toxin-induced model (12, 13). 
Delineating the mechanisms that underlie the demyelinating versus remyelinating functions of  microglia/
macrophages should lead to novel therapeutic targets.
TNF is a master proinflammatory product of  activated microglia and peripheral macrophages that is 
implicated in the pathogenesis of  CNS demyelination. TNF induces OLG death and myelin damage when 
added to mouse spinal cord cultures (14) and triggers spontaneous demyelination when overexpressed in 
CNS glia of  transgenic mice (15). On the other hand, in an experimental model of  demyelination and 
remyelination induced by dietary cuprizone (CPZ), TNF-deficient (Tnf–/–) mice demyelinate but fail to 
remyelinate, and they show reduced numbers of  proliferating OPC in lesions, pointing to a critical role of  
TNF in CNS remyelination (16). Since TNF comprises, at minimum, a two-ligand (soluble and transmem-
brane TNF) and two-receptor (TNFR1 and TNFR2) system — with ligands and receptors being differen-
tially expressed and regulated on different cell types (17) — identification of  the TNF ligand/receptor pairs 
and cellular mechanisms involved in remyelination might lead to the development of  novel therapeutics for 
the treatment of  progressive MS. Previous studies showed that TNFR2 is necessary for OPC proliferation 
and remyelination after the removal of  dietary toxin in the CPZ model (16). Further, selective inhibition of  
soluble TNF (solTNF) by the administration of  XPro1595, a dominant-negative TNF analogue (18), but 
not nonselective inhibition of  solTNF and transmembrane TNF (tmTNF) by etanercept, promotes remy-
elination in EAE (19). These findings, together with recent evidence that oligodendroglial TNFR2 is suf-
ficient for TNF-mediated remyelination in EAE (20), provide strong evidence that tmTNF promotes remy-
elination via TNFR2 present on oligodendroglial cells. However, it is not clear whether solTNF inhibits the 
remyelination process directly or indirectly by increasing neuroinflammation. In this study, we exploited 
our finding that XPro1595 can penetrate the intact brain, using it to investigate the role of  solTNF in a 
CPZ model. We show that therapeutic inhibition of  solTNF in the brain by XPro1595 does not prevent 
OLG loss or demyelination, but permits early myelin repair and preservation of  axons by enhancing the 
phagocytosis of  myelin debris in demyelinated lesions by CNS macrophages. Studies in Tnf–/– and tmTNF-
knockin (tmTnfΔ/Δ) mice further show that tmTNF is necessary for the beneficial effects of  XPro1595. Col-
lectively, our data demonstrate opposing effects of  solTNF and tmTNF in inhibiting and promoting CNS 
remyelination, respectively, and suggest that selective inhibition of  solTNF by brain-penetrating agents 
such as XPro1595 represents a promising approach for enhancing endogenous CNS repair mechanisms in 
progressive MS.
Results
CPZ-induced demyelination is a well-characterized and highly reproducible experimental model for 
studying mechanisms of  CNS demyelination and remyelination in mice of  susceptible strains, including 
C57BL/6 (B6) (21). CPZ is a copper chelator, and CPZ feeding induces copper deficiency, the selective 
death of  OLG, and CNS demyelination that is readily measurable in the corpus callosum (22). Demyelin-
ation is associated with CNS-compartmentalized neuroinflammation that develops behind an intact BBB 
(23), although blood-derived neutrophils also play critical roles in early disease (24). CPZ administration 
for 6 weeks in young-adult B6 mice induces acute demyelination followed by almost-complete remyelin-
ation in the weeks after CPZ withdrawal (21), while administration for 12 weeks or more causes chronic 
demyelination and irreversible axonal damage (25). The acute model is particularly useful for studying 
OPC responses to demyelination and remyelination, as well as key aspects of  progressive MS such as oxi-
dative damage and mitochondrial injury in the presence of  chronically activated microglia (7).
Local inhibition of  solTNF in the brain promotes myelin recovery after CPZ-induced demyelination. Acute demy-
elination was induced in WT B6 mice as described (21). In this model, demyelination shows a highly repro-
ducible time course of  pathological and gene expression changes (21, 22, 26, 27). Severe demyelination 
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Figure 1. Therapeutic inhibition of soluble TNF in brain does not alter cuprizone-induced demyelination but promotes myelin recovery in a transmem-
brane TNF-dependent manner. (A) Klüver-Barrera Luxol fast blue staining (LFB) and 2’, 3’-cyclic nucleotide 3’-phosphodiesterase (CNPase) immunostain-
ing of myelin in serial brain coronal paraffin sections from representative vehicle- (left column), XPro1595- (middle column), and etanercept-treated (right 
column) naive mice (CPZ0) or cuprizone-fed (CPZ-fed) CPZ3, CPZ5, CPZ6+1, and CPZ6+4 mice (n = 8 for vehicle-treated CPZ0, n = 4 for XPro1595-treated 
CPZ0, and n = 6–12 for all other time points). Scale bars: 500 μM. (B) Semiquantitative scoring of demyelination (loss of LFB staining) in the callosum of 
the same groups of mice represented in A. (C) Levels of Tnf mRNA transcripts relative to Gusb in whole brain samples from vehicle-treated CPZ0 and CPZ2, 
CPZ3, CPZ5, and CPZ6+1 mice by quantitative PCR (n = 4 per group). (D) Human TNF levels in brain and serum from vehicle- and XPro1595-treated CPZ0 
and XPro1595-treated CPZ5 mice using a human TNF immunoassay (n = 5 per group). (E) Semiquantitative scoring of demyelination (loss of LFB staining) 
in coronal paraffin sections of corpus callosum of vehicle- and XPro1595-treated CPZ0, CPZ3, and CPZ5 WT, Tnf–/–, or tmTnfΔ/Δ mice (n = 6–8 per group). 
The results shown are from one representative ([E] Tnf–/–, tmTnfΔ/Δ) of two (C and D) or three ([A, B, and E] WT) independent experiments. Statistical 
significance after comparisons between measurements of demyelination in the different mouse strains (B and E) and mRNA levels (C) by two-way ANOVA 
with Bonferroni’s test and ordinary one-way ANOVA with Tukey’s test, respectively, is shown. *P < 0.05, **P < 0.01, ***P < 0.001. (B and E) Comparisons 
between measurements of demyelination in CPZ0 mice with other groups are all significant and not annotated on the plots. (A) Asterisks show early 
recovery of myelin. (B, C, and E) Circles show values for individual mice.
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occurred in the corpus callosum after both 3 (CPZ3) and 5 (CPZ5) weeks of  CPZ feeding, compared with 
naive (CPZ0) controls, as shown by Klüver-Barrera Luxol fast blue staining (LFB) (Figure 1A and Figure 1B) 
and immunostaining for 2’, 3’-cyclic 3’-phosphodiesterase (CNPase) (Figure 1A and Supplemental Figure 
1A; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.87455DS1). 
The corpus callosum in CPZ-fed vehicle-treated WT mice showed an increase in total volume at both CPZ3 
(2.56 ± 0.08 mm3) and CPZ5 (2.82 ± 0.03 mm3) compared with CPZ0 (2.25 ± 0.04 mm3), despite significant 
demyelination (Supplemental Figure 2A), possibly as a combined result of  reduced myelin compaction and 
increased numbers of  inflammatory cells (see below). Adjustment of  LFB measurements at each experi-
mental time point to incorporate these differences showed similar results (Supplemental Figure 2B). CPZ 
removal from the diet at week 6 (CPZ6) was followed by progressive recovery of  myelin as measured after 
1 (CPZ6+1) and 4 (CPZ6+4) weeks (Figure 1A, Figure 1B, and Supplemental Figure 1A). In parallel with 
the histopathological changes, and as reported in B6 mice (26, 27), levels of  mRNA encoding the structural 
protein myelin basic protein (MBP) in total brain were dramatically reduced at the CPZ2, CPZ3, and CPZ5 
time points and recovered again following CPZ removal (CPZ6 + 1) (Supplemental Figure 1B).
Using genetic models, TNF was previously shown to advance the onset of  CPZ-induced demyelin-
ation and OLG death, and to promote the remyelination process after withdrawal of  dietary CPZ (16), 
suggesting that it may have different effects at different stages of  pathology. Here, we found that brain 
TNF mRNA levels consistently showed a small, nonsignificant increase at CPZ2 and a second increase 
at CPZ6+1, when remyelination is occurring in WT mice (Figure 1C). To investigate possible differential 
roles of  solTNF and tmTNF during the development of  demyelination and remyelination, we adminis-
tered XPro1595 systemically to WT, Tnf–/–, or tmTnfΔ/Δ mice. XPro1595 is a TNF inhibitor designed by 
mutating key amino acids in human solTNF to eliminate binding to TNFR1 and TNFR2. Similarly to the 
genetic concept of  dominant-negative inhibitors, XPro1595 exchanges subunits with and thus destroys the 
native homotrimeric solTNF ligand, while fully preserving tmTNF activity (18, 28). XPro1595 is equally 
inhibitory against mouse solTNF and equally protective of  mouse tmTNF, as it is for human TNF (28). We 
treated WT mice using a therapeutic protocol whereby XPro1595 was administered twice-weekly starting 
from the end of  the second week of  feeding (at the onset of  first histopathological changes), and we sac-
rificed mice at different time points during and after CPZ feeding. XPro1595 administration did not alter 
initial demyelination, which was equal to that in vehicle-treated controls at CPZ3 (Figure 1A, Figure 1B, 
and Supplemental Figure 1A). However, XPro1595 stimulated the early recovery of  myelin at CPZ5 com-
pared with vehicle controls, a time point where CPZ was still present in the diet (Figure 1A, Figure 1B, and 
Supplemental Figure 1A). The corpus callosum volume in XPro1595-treated WT mice showed an equal 
increase to that in vehicle-treated controls at both CPZ3 (2.58 ± 0.02 mm3) and CPZ5 (2.87 ± 0.09 mm3) 
compared with CPZ0 (2.33 ± 0.03 mm3) (Supplemental Figure 2A). Adjustment of  LFB measurements at 
each experimental time point to incorporate these differences in XPro1595-treated mice revealed similar 
results (Supplemental Figure 2B).
Since CPZ demyelination is not associated with BBB damage (23), we checked whether peripherally 
administered XPro1595 reached the brain. We measured levels of  XPro1595 in serum and brain homog-
enates from CPZ0 and CPZ-treated mice that were treated with XPro1595 or saline for 3 weeks prior to 
sacrifice at CPZ5 (6 injections) using an antibody specific for human TNF, which recognizes the human 
dominant negative TNF protein epitopes in XPro1595 but not mouse TNF. No XPro1595 signal was 
detectable in brains from vehicle-treated naive mice (Figure 1D). In contrast, equal levels of  XPro1595 
were measured in brains from XPro1595-treated naive and CPZ-fed mice, and were in the range of  400 pg/
ml (PBS-perfused mice) (Supplemental Figure 3) to 3,000 pg/ml (nonperfused mice) (Figure 1D). Levels of  
XPro1595 in the sera from XPro1595-treated mice were more than 1,000-fold higher than levels detected 
in the CNS on the day of  sacrifice, suggesting an inefficient yet still pharmacologically relevant flux across 
the BBB. As pathological levels of  TNF in the CNS have been reported to be in the picogram per ml range 
(29), the measured levels of  XPro1595 are predicted to inhibit > 99% of  solTNF in the brain (18). These 
results show that XPro1595 penetrates and accumulates in the brain at pharmacologically relevant levels.
To exclude the participation of  peripherally derived TNF in the effects observed, we treated mice by 
twice-weekly s.c. injection of  etanercept (10 mg/kg), a nonselective inhibitor that blocks both solTNF and 
tmTNF (30), according to our therapeutic protocol. Etanercept is a human TNFR2-Fc (IgG1) fusion pro-
tein that blocks both solTNF and tmTNF and minimally penetrates the BBB (31). Etanercept did not pre-
vent initial demyelination, which was equal to that in XPro1595- and vehicle-treated mice at CPZ3, nor did 
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it alter the subsequent recovery of  myelin at CPZ5 (Figure 1A, Figure 1B, and Supplemental Figure 1A). 
This result shows that peripherally derived TNF does not contribute to demyelination or remyelination in 
the CPZ model and indicates that XPro1595 promotes myelin recovery by inhibiting solTNF locally in 
the CNS. To verify that peripherally administered etanercept has limited brain penetrance, we measured 
Figure 2. Therapeutic inhibition of soluble TNF in brain does not alter acute cuprizone-induced axon damage but prevents its progression in the corpus callo-
sum in a TNF-dependent manner. (A) Bielschowsky’s silver staining (Biel) and neurofilament H nonphosphorylated (SMI 32) immunostaining of axons in brain 
coronal sections from representative vehicle- (left column), XPro1595- (middle column), and etanercept-treated (right column) naive mice (CPZ0) or cuprizone-
fed (CPZ-fed) CPZ3, CPZ5, CPZ6+1, and CPZ6+4 mice (n = 8 for vehicle-treated CPZ0, n = 4 for XPro1595-treated CPZ0, and n = 6–12 for other time points). The 
area used for quantitating axon damage is shown in the vehicle-treated Bielschowsky-stained CPZ0 sample. Scale bars: 500 μM for Bielschowsky, 50 μM for 
SMI 32. (B) Quantitative representation of SMI 32 immunoreactivity in the corpus callosum of groups of mice represented in A. (C) Levels of Snap25 mRNA 
transcripts relative to Gusb in whole brain samples from CPZ0, CPZ3, CPZ5, CPZ6+1, and CPZ6+4 mice by quantitative PCR (n = 4 per group). (D) Quantitative 
representation of SMI 32 immunoreactivity in the corpus callosum of vehicle- and XPro1595-treated CPZ0 and CPZ5 Tnf–/– or WT mice (n = 6–8 per group). The 
results shown are from one representative ([D] Tnf–/–) of two (C) or three ([A, B, and D] WT) independent experiments. Statistical significance after comparisons 
between measurements of immunoreactivity in the different mouse strains (B, D) and mRNA levels (C) by two-way ANOVA with Bonferroni’s test and ordinary 
one-way ANOVA with Tukey’s test, respectively, is shown. *P < 0.05, **P < 0.01, ***P < 0.001. (A) Asterisks show maintenance of axon integrity. (B–D) Circles 
show values for individual mice.
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levels of  etanercept in serum and brain homogenates from CPZ0 and CPZ-fed mice that were treated with 
etanercept or saline for 3 weeks prior to sacrifice at CPZ5 (6 injections) using an immunoassay specific for 
human TNFR2 that does not cross-react with mouse TNFR2. Low levels of  etanercept, approximately 100 
times lower than those of  XPro1595, were detectable in brain homogenates from PBS-perfused etanercept-
treated naive or CPZ-fed (2–3 pg/ml) mice but not from vehicle-treated mice (Supplemental Figure 3). 
These results show that etanercept fails to accumulate at significant levels in the brain of  naive or CPZ-
treated animals.
Given that TNF and TNFR2, which is activated by tmTNF (32), are reported to play a role in OLG 
and myelin regeneration (16), we first checked whether the increased recovery of  myelin in XPro1595-
treated animals was dependent on TNF, and therefore by deduction tmTNF, by administering XPro1595 
to CPZ-fed Tnf–/– mice. Vehicle-treated Tnf–/– mice lacking both solTNF and tmTNF developed robust and 
equal demyelination at CPZ5, similar to that in vehicle-treated WT mice (Figure 1E). Unlike WT mice, 
however, XPro1595-treated Tnf–/– mice did not show myelin recovery at this time point, suggesting that 
tmTNF is necessary for the myelin recovery seen in XPro1595-treated WT mice (Figure 1E). To confirm a 
role for tmTNF in the maintenance of  myelin, we next administered XPro1595 to CPZ-fed tmTNFΔ/Δ mice, 
which carry an uncleavable TNF allele and constitutively produce functional, normally regulated tmTNF 
without solTNF (33). Naive (CPZ0) vehicle- and XPro1595-treated tmTNFΔ/Δ mice showed normal myelin-
ation, similar to that in WT and Tnf–/– mice, as determined by LFB staining. CPZ-fed tmTNFΔ/Δ mice devel-
oped demyelination in response to CPZ feeding, similar to that in WT mice at CPZ3, but demyelination 
did not progress further at CPZ5, as it did in WT and Tnf–/– mice (Figure 1E). As expected, XPro1595 
administration did not improve myelin levels in tmTNFΔ/Δ mice at either CPZ3 or CPZ5 (Figure 1E). Taken 
together, these results reveal a previously unknown role for solTNF in inhibiting myelin repair, as shown by 
early myelin recovery following XPro1595 treatment in WT mice. They also reveal that tmTNF is neces-
sary for early remyelination in XPro1595-treated WT mice, as shown by the failure of  myelin recovery in 
XPro1595-treated Tnf–/– mice, and maintenance of  myelin integrity in tmTNFΔ/Δ mice, at CPZ5.
Inhibition of  brain solTNF reduces CPZ-induced axonal damage. Although neuronal pathology is not well-
studied in the CPZ model, demyelination is associated with axon damage, and its severity increases with 
age (34) and duration of  treatment (25). Consistent with this, CPZ feeding in vehicle-treated mice induced 
progressive axon damage in the corpus callosum, as monitored at CPZ3 and CPZ5 by a reduction of  Biel-
schowsky’s Biel silver-stained axons (Figure 2A) and an increase in area covered by SMI 32 immunostain-
ing for nonphosphorylated neurofilament H (Figure 2B). Adjustment of  SMI 32 immunostaining results 
at CPZ0, CPZ3, and CPZ5 to incorporate differences in corpus callosum volume between groups showed 
similar results (Supplemental Figure 2C). Axon damage was almost completely absent by 1 week after CPZ 
withdrawal (Figure 2A and Figure 2B), showing that axon damage in this acute model is reversible. Levels 
of  mRNA encoding the synaptic protein Snap25 in total brain were reduced at the CPZ3 and CPZ5 time 
points and progressively recovered again after CPZ withdrawal (CPZ6+1, CPZ6+4) (Figure 2C).
Inhibition of  solTNF by XPro1595 treatment did not prevent initial axon damage measured at CPZ3, 
but it prevented the further progression of  damage at CPZ5 in the vehicle-treated group (Figure 2A, Figure 
2B, and Supplemental Figure 2C). Etanercept treatment had no effect on axonal damage at any time point, 
as monitored by Biel silver staining (Figure 2A) or SMI 32 immunostaining (Figure 2A and Figure 2B), 
suggesting that peripherally derived TNF does not contribute to axon damage in the CPZ model. These 
results show that local inhibition of  solTNF in the brain by XPro1595 prevents the progressive accumula-
tion of  axon damage in the corpus callosum during CPZ administration.
tmTNF and its two receptors, TNFR1 and TNFR2, are known to be important for neuroprotection (17, 
35). Therefore, we investigated whether protection against axonal damage in XPro1595-treated animals is 
dependent on TNF, and therefore by tmTNF, by administering XPro1595 to CPZ-fed Tnf–/– mice. As in WT 
mice, vehicle-treated Tnf–/– mice lacking both solTNF and tmTNF developed axonal damage, as measured 
by SMI 32 immunoreactivity, at CPZ5 (Figure 2D). Unlike in WT mice, where XPro1595 treatment prevent-
ed further axon damage at this time point, Tnf–/– mice treated with XPro1595 showed equal axonal damage 
as vehicle-treated controls (Figure 2D). Taken together, these results show that local inhibition of  solTNF in 
the brain protects against progressive CPZ-induced axonal damage. In addition, our observations that axo-
nal damage fully develops in Tnf–/– mice, which lack both solTNF and tmTNF, and that XPro1595-mediated 
protection is abrogated by TNF deficiency, support a role for tmTNF in axon protection, most likely as an 
indirect result of  its positive effects on myelin.
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Inhibition of  solTNF in the brain promotes early resolution of  microgliosis in demyelinated lesions. CPZ feeding 
in vehicle-treated mice was associated with microglia activation at CPZ3 and full-blown confluent microg-
liosis at CPZ4 and CPZ5 in the demyelinating callosum, as measured by area covered by immunostaining 
for ionized calcium-binding adaptor molecule 1 (Iba1) (Figure 3, A and B, and Supplemental Figure 4A) 
and numbers of  Iba1-immunostained cells by stereology (Figure 3C), consistent with previous findings 
(36). CPZ feeding in vehicle-treated mice was also associated with astrocyte activation at CPZ5 in the 
corpus callosum, as measured by area covered by glial fibrillary acidic protein (GFAP) immunostaining 
(Supplemental Figure 2D). In parallel with these pathological changes, and as reported in B6 mice (26), 
brain levels of  mRNAs encoding inflammatory cytokines and mediators, including main products of  acti-
vated glia such as TNF (Figure 1C), CCL2, and CXCL16, were increased during CPZ feeding with two 
peaks of  expression: one after the initiation of  CPZ feeding and another at CPZ6+1, when remyelination 
is occurring (Supplemental Figure 4, B and C).
XPro1595 treatment in CPZ-fed mice did not prevent early microglia activation at CPZ3 or conflu-
ent microgliosis at CPZ4, but it stimulated early resolution of  microgliosis at CPZ5 and CPZ6+1, as 
measured by reduced areas of  Iba1 immunoreactivity in the corpus callosum (Figure 3, A and B, and 
Figure 3. Therapeutic inhibition of soluble 
TNF in brain promotes early resolution 
of microgliosis in demyelinated lesions. 
(A) Immunostaining for Ionized calcium-
binding adaptor molecule 1 (Iba1) and 2’, 
3’-cyclic nucleotide 3’-phosphodiesterase 
(CNPase) in serial coronal paraffin sections 
of corpus callosum from representative 
vehicle- (left column) and XPro1595-treated 
(right column) CPZ0, CPZ3, CPZ4, and CPZ5 
mice (n = 8 for vehicle-treated CPZ0, n = 4 
for XPro1595-treated CPZ0, and n = 6–12 for 
all other time points). Scale bars: 100 μM. (B) 
Quantitative representation of area covered 
by Iba1 immunoreactivity in the callosum in 
groups of mice represented in A. (C) Num-
bers of Iba1-immunoreactive microglia/mm3, 
as measured by stereology in brain coronal 
cryostat sections through callosum from 
representative vehicle- and XPro1595-treat-
ed CPZ0 and CPZ5 mice (n = 3–4 for each 
group). (D) Levels of Chil3 and Il-1β mRNA 
transcripts relative to Gapdh in whole brain 
samples from vehicle- and XPro1595-treated 
CPZ0 and CPZ5 mice by quantitative PCR (n 
= 3–4 per group). (E) Quantitative represen-
tation of area covered by Iba1 immunoreac-
tivity in coronal paraffin sections of corpus 
callosum of vehicle- and XPro1595-treated 
CPZ0 and CPZ5 Tnf–/– or WT mice (n = 6–8 
per group). The results shown are from one 
representative ([C, D, and E] Tnf–/–) of three 
([A, B, and E] WT) independent experiments. 
Statistical significance after comparisons 
between areas of Iba1 immunoreactivity in 
the different mouse strains (B and E), num-
bers of Iba1-immunoreactive cells (C), and 
brain mRNA levels (D) by two-way ANOVA 
with Bonferroni’s test, is shown. *P < 0.05, 
**P < 0.01, ***P < 0.001. (A) Asterisks show 
early resolution of microgliosis accompany-
ing recovery of myelin. (B, C, D, and E) Circles 
show values for individual mice.
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Supplemental Figure 4A, middle column, asterisks), without altering numbers of  Iba1-immunoreactive 
cells — as measured by stereology (Figure 3C) — compared with the vehicle-treated groups. Interest-
ingly, early resolution of  microgliosis in XPro1595-treated mice correlated with early recovery of  myelin 
at CPZ5 (Figure 1A, middle column and Figure 3A, right column). In contrast, XPro1595 treatment did 
not alter astrocyte activation at CPZ5, which was equal to that in vehicle-treated CPZ5 mice (Supple-
mental Figure 2D).
Measurement of  mRNA transcripts for Chil3 (Ym1), a chitinase-like 3 protein that is associated with 
host defense (37) and used as a marker for protective alternatively activated macrophages, showed low-level 
brain expression in vehicle-treated mice at CPZ0 that was upregulated at CPZ5 (Figure 3D). Conversely, 
XPro1595 treatment induced marked upregulation of  Chil3 in naive mice at CPZ0 that was downregulated 
to levels equal to those in vehicle-treated mice at CPZ5 (Figure 3D). In contrast, mRNA levels for brain 
IL-1β, a cytokine important for remyelination (38) and a marker for proinflammatory macrophages, were 
not altered by dietary CPZ in vehicle-treated mice at CPZ0 or CPZ5 but were upregulated by XPro1595 
treatment in CPZ5 mice (Figure 3D). Brain mRNA levels for other markers of  proinflammatory and alter-
natively activated macrophages — Nos2 (iNos) and Arg-1, respectively — were not altered by dietary CPZ 
or XPro1595 treatment (data not shown). Etanercept treatment had no effect on the area of  callosum 
covered by Iba1 immunoreactivity in naive or CPZ-fed animals compared with the vehicle-treated group 
(Figure 3B and Supplemental Figure 4A right column).
The finding that selective inhibition of  solTNF with XPro1595 regulated microglia responses in the 
CPZ-induced demyelination model is consistent with the already known proinflammatory roles of  this 
cytokine in the CNS (17). To investigate a possible role for tmTNF in CPZ-induced microglia reactivity, 
we also administered XPro1595 to CPZ-fed Tnf–/– mice. Unlike in WT mice, where XPro1595 treatment 
resolved microgliosis at CPZ5 as measured by area covered by Iba1 immunostaining, Tnf–/– mice treated 
with XPro1595 showed equal microgliosis as vehicle-treated controls (Figure 3E). Taken together, these 
results suggest that local inhibition of  solTNF in the brain markedly regulates the phenotype of  microglia, 
priming them toward an alternatively activated phenotype in naive mice and markedly reducing microglio-
sis at CPZ5, a time point at which XPro1595 treatment has profoundly promoted myelin recovery. In addi-
tion, the observations that full-blown microgliosis accompanies CPZ-induced demyelination at CPZ5 in 
XPro1595-treated Tnf–/– mice, which lack both solTNF and tmTNF, strongly support an antiinflammatory 
effect of  tmTNF, possibly as an indirect result of  its positive effects on myelination and neuroprotection.
Inhibition of  solTNF in brain increases oligodendrocyte progenitor cell numbers in demyelinated lesions. Demy-
elination in the callosum of  vehicle-treated CPZ-fed mice was associated with a robust OPC response, as 
measured by increased numbers of  PDGFRα-immunoreactive OPC at all time points (Figure 4, A and 
B), and increased area covered by PDGFRα immunoreactivity at CPZ3 (Supplemental Figure 5A), com-
pared with naive animals. The response was associated with increased OPC proliferation, as shown by the 
increased proportions of  OPC immunostained for platelet-derived growth factor receptor alpha (PDGFRα) 
cells double-stained for Ki67 protein in the callosum at CPZ3 and CPZ5 compared with CPZ0 (Figure 4C). 
In the CPZ model used here, OPC start differentiating at CPZ5 to become mature, myelinating OLG by 
CPZ6 in WT mice (22, 39). This time course was reflected by increased levels of  Olig2 mRNA transcripts at 
CPZ5 (Figure 4D) and Mbp mRNA transcripts at CPZ6+1 (Supplemental Figure 1B), recovery of  myelin 
measured at CPZ6+1 and CPZ6+4 (Figure 1, A and B), and a drop in OPC numbers at CPZ6+1 compared 
with CPZ5 (Figure 4B), possibly due to OPC differentiation.
Demyelination in the callosum of  XPro1595-treated mice was also associated with a robust OPC 
response, measured by increased numbers of  PDGFRα-immunoreactive OPC (Figure 4, A and B), and 
increased area covered by PDGFRα immunoreactivity at CPZ3 and CPZ5 (Supplemental Figures 2E 
and 5A), compared with naive animals. In CPZ3 lesions, the OPC response was equal but, at CPZ5, was 
increased compared with vehicle- and etanercept-treated mice (Figure 4, B and E, and Supplemental Figure 
5A). OPC proliferation increased in XPro1595-treated CPZ-fed mice equally to that in vehicle controls 
(Figure 4C). To investigate a possible role for tmTNF in CPZ-induced OPC responses, we administered 
XPro1595 to CPZ-fed Tnf–/– mice. As expected, OPC numbers were not increased in CPZ5 lesions of  
XPro1595-treated compared with vehicle-treated Tnf–/– mice, as they were in WT mice (Figure 4E).
To evaluate whether the increased OPC response in XPro1595-treated mice at CPZ5 was due to dif-
ferences in OPC differentiation, we tested the effects of  XPro1595 and solTNF on OPC differentiation 
in vitro, using mixed cortical neuron-glial cultures, which contain significant numbers (around 6%) of  
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OPC immunostained for NG2 chondroitin sulfate proteoglycan (NG2) (Supplemental Figure 5, B and 
C). Cultures were incubated in the presence of  XPro1595, murine solTNF, or medium alone, and the pro-
portions of  cells positive for NG2 (an OPC marker) and O4 (a marker of  pre-myelinating and myelinating 
OLG), compared with total DAPI-stained cell nuclei, were measured. A small number of  cells showed 
double immunoreactivity for NG2 and O4 under all culture conditions, suggestive of  low-level OPC 
Figure 4. Inhibition of soluble TNF in brain increases OPC response in demyelinated lesions. (A) Platelet-derived growth factor receptor α (PDGFRα) immu-
nostaining of oligodendrocyte progenitor cells (OPC) in coronal paraffin sections of corpus callosum from representative vehicle- (left column), XPro1595- 
(middle column), and etanercept-treated (right column) CPZ0, CPZ3, CPZ5, CPZ6+1, and CPZ6+4 mice (n = 8 for vehicle-treated CPZ0, n = 4 for XPro1595-
treated CPZ0, and n = 6–12 for other time points). Scale bars: 100 μM. (B) Quantification of PDGFRα-immunoreactive cells/mm2 in the callosum in groups 
of mice represented in A. (C) Proportions of PDGFRα-immunoreactive cells double-stained for the proliferation marker Ki67 in the callosum, in groups of 
mice represented in A. (D) Levels of Olig2 mRNA transcripts relative to Gusb in whole brain samples of vehicle-treated mice isolated from CPZ0, CPZ2, CPZ3, 
CPZ5, and CPZ6+1 mice by quantitative PCR, (n = 4 per group). (E) Numbers of PDGFRα-immunoreactive cells/mm2 in the callosum of vehicle- and XPro1595-
treated CPZ0 and CPZ5 Tnf–/– and WT mice (n = 6–8 per group). The results shown are from one representative ([E] Tnf–/–) of two (D) or three ([A, B, C, and E] 
WT) independent experiments. Statistical significance after comparisons between numbers of PDGFRα-immunoreactive cells in the different mouse strains 
(B and E) and proportions of double positive cells (C) by two-way ANOVA with Bonferroni’s test and mRNA levels (D) by ordinary one-way ANOVA with 
Tukey’s test are shown. *P < 0.05, **P < 0.01, ***P < 0.001. (B, C, D, and E) Circles show values for individual mice.
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differentiation in these conditions (Supplemental Figure 5B). The proportions of  NG2-positive OPC 
and O4-positive OLG were very low, but equal in untreated, XPro1595, and TNF cultures at all time 
points measured.
These results indicate that solTNF does not alter the proliferation or differentiation capacity of  OPC, 
but it inhibits their accumulation in the demyelinated lesions. They also suggest that TNF, by deduction 
tmTNF, is necessary for OPC accumulation in the demyelinating lesions.
Inhibition of  solTNF in brain promotes remyelination and prevents decline of  motor performance. To investigate 
whether the increased numbers of  PDGFRα-immunoreactive OPC (Figure 4, B and E) and myelin (Figure 1B) 
Figure 5. Inhibition of soluble TNF in brain improves myelin compaction and promotes remyelination after CPZ-induced demyelination. (A) Elec-
tron micrographs of corpus callosum from vehicle- (left column) and XPro1595-treated (right column) CPZ0 and CPZ4 mice showing myelinated axons 
(arrowheads) (n = 3 per group). Scale bars: 1 μM. Insets show myelin at higher magnification. Scale bar: 150 nM. (B) Numbers of myelinated axons in corpus 
callosum (1 × 103/mm2). (C) Quantification of the g-ratios (axon area/fiber area) of myelinated fibers in the same mice as in A. (D) Scatter plot showing 
distribution of g-ratios against axonal caliber in same mice as in A. Statistical significance after comparisons between measurements of g-ratios (B) and 
numbers of myelinated axons (C) by one-way ANOVA with Tukey’s test is shown. ***P < 0.001. (B) Circles show values for individual mice.
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in XPro1595-treated CPZ5 mice correlated with improved remyelination, we used electron microscopy to 
measure the numbers and g-ratios of  myelinated axons and to evaluate the morphology of  myelin in the cor-
pus callosum at CPZ4. XPro1595-treated naive (CPZ0) mice showed normal myelin thickness and numbers 
of  myelinated axons (Figure 5, A–C). CPZ feeding induced profound demyelination in vehicle-treated mice 
by CPZ4, as seen by the almost complete absence of  myelinated axons (Figure 5, A and B), although the 
few remaining myelinated axons showed normal g-ratio, indicating they had not undergone demyelination 
(Figure 5C). XPro1595 treatment did not prevent demyelination, as seen by LFB staining at CPZ3 (Figure 1, 
A and B) and loss of  myelinated axons compared with XPro1595-treated naive mice by electron microscopy 
at CPZ4 (Figure 5B), but it significantly increased the numbers of  thinly myelinated axons characteristic 
of  remyelination (Figure 5A), as measured by higher g-ratios (Figure 5, C and D), and increased numbers 
of  myelinated axons (Figure 5B) compared with vehicle controls. Regression analysis of  g-ratios and axon 
diameters revealed that XPro1595 treatment enhanced remyelination of  all axon sizes, including large-cali-
ber axons, compared with vehicle treatment where small-caliber axons were preferentially remyelinated (Fig-
ure 5D). These results show that local inhibition of  solTNF in the brain resulted in accelerated remyelination 
of  demyelinated axons in the corpus callosum at CPZ4.
To test whether improved remyelination in XPro1595-treated mice was accompanied by better motor 
performance, we tested mice for overall balance, motor coordination, and motor learning using a rotarod 
apparatus following procedures described elsewhere (40). Motor function was reduced in vehicle-treated 
mice at CPZ5, as measured by marked reduction in time spent on the rotating cylinder, compared with 
naive mice (Figure 6). XPro1595 treatment did not affect the motor performance of  naive CPZ0 mice at 
any time point tested and completely prevented the decline in motor function induced by CPZ, as measured 
by equal times spent on the rotating cylinder by XPro1595-treated CPZ mice and naive mice at all time 
points tested (Figure 6).
These results show that XPro1595 treatment promotes the remyelination of  demyelinated axons in the 
callosum during CPZ feeding and prevents the CPZ-induced decline in motor function.
solTNF inhibition enhances myelin uptake by Mac3-immunoreactive phagocytes. In the acute CPZ model used 
here, OLG apoptosis starts as early as a few days after the initiation of  CPZ and results in massive OLG 
death by week 4 (41) (Figure 7B). To determine whether solTNF contributes to OLG death, we treated 
B6 mice with twice-weekly s.c. injections of  XPro1595 (10 mg/kg) or saline vehicle using a prophylactic 
protocol starting 2 weeks before CPZ feeding (6 injections), and we sacrificed mice at different time points 
for histopathological analysis. Overall, as with the therapeutic protocol (Figure 1), there was no significant 
difference in demyelination and OLG pathology in the corpus callosum between XPro1595- and vehicle-
treated mice. Thus, XPro1595 did not alter the progressive loss of  CNPase-immunoreactive OLG (Figure 
7, A and B), or the numbers of  CNPase-immunoreactive OLG with apoptotic nuclei (Figure 7B), compared 
with vehicle-treated mice over time. Further, XPro1595 did not alter the presence of  damaged myelin, 
which was measured by massively increased immunoreactivity for proteolipid protein (PLP) due to the 
unmasking of  protein epitopes, compared with vehicle over time (Figure 7A. However, while XPro1595- 
and vehicle-treated mice showed similar total numbers of  Mac3-positive macrophages in the lesions, which 
progressively increased over time (Figure 7C), there were higher proportions of  large macrophages contain-
ing PLP-immunoreactive myelin degradation products in XPro1595-treated lesions compared with vehicle 
controls (Figure 7, A and D). Further, XPro1595-treated mice at CPZ4 revealed areas highly infiltrated by 
Figure 6. Inhibition of soluble TNF in brain prevents decline of motor 
performance. Rotarod test in vehicle- and XPro1595-treated naive and 
cuprizone-treated (CPZ-treated) mice at different time points. Vehicle- 
and XPro1595-treated mice at experimental week 3 (naive vehicle-
treated, n = 9; naive XPro1595-treated, n = 9; vehicle-treated CPZ3, n = 14; 
XPro1595-treated CPZ3, n = 14), week 4 (n = 9, n = 6, n = 9, n = 9, respec-
tively), weeks 5 and 6 (n = 7, n = 4, n = 5, n = 5, respectively). The lengths 
of time the mice stayed on the accelerating cylinder (4–40 rpm) were 
recorded. Statistical significance after comparisons between all groups at 
each time point were performed using two-way ANOVA with Bonferroni’s 
test. *P < 0.05. Circles show values for individual mice.
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Figure 7. Inhibition of soluble TNF increases the clearance of myelin debris by phagocytic CNS macrophages and the production of new myelin in 
demyelinated lesions. (A) 2’, 3’-cyclic nucleotide 3’-phosphodiesterase (CNPase) immunostaining of oligodendrocytes (OLG) (left column), proteolipid 
protein (PLP) immunostaining of myelin (right column, blue), and Mac3 immunostaining of CNS macrophages (right column, red) in coronal paraffin sec-
tions of corpus callosum from CPZ0 or CPZ-fed mice. At each time point, representative sections from vehicle-treated (CPZ3, CPZ4, CPZ5; upper rows) or 
XPro1595-treated (CPZ0, CPZ3, CPZ4, CPZ5; lower rows) mice are shown (n = 5 per group). PLP immunoreactivity is massively increased in degenerating 
myelin that has lost OLG support (CPZ3, CPZ4, CPZ5). Scale bars: 100 μM. (B) Total numbers of CNPase-immunoreactive OLG/field (×40) (bars, left axis), 
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Mac3-positive macrophages that largely lacked CNPase and PLP-reactive myelin (Figure 7A). These were 
not observed in vehicle-treated animals, suggesting efficient clearance of  myelin debris in XPro1595-treated 
animals. By CPZ5, both XPro1595- and vehicle-treated mice showed areas containing thin CNPase-immu-
nostained myelin sheaths and weak expression of  PLP, consistent with new myelin formation, and these 
remyelinating areas appeared larger in XPro1595-treated mice (Figure 7A). These results strongly indicate 
that selective inhibition of  solTNF in the brain promotes myelin debris clearance by Mac3-immunoreactive 
macrophages (microglia), which in turn allows more-efficient remyelination of  demyelinated axons.
To test whether solTNF directly affects macrophage phagocytic activity, we performed in vitro myelin 
phagocytosis assays using mouse macrophage cells in the absence and presence of  XPro1595, and we 
measured myelin uptake by immunocytochemistry using anti-MBP antibodies (Supplemental Figure 6). 
Significantly larger proportions of  macrophages containing MBP immunoreactivity were measured with 
XPro1595-supplemented medium compared with nonsupplemented medium by 40 hours of  culture (Fig-
ure 7E). These data show that XPro1595 directly increases the ability of  mouse macrophages to phagocy-
tose myelin in vitro —and in vivo in CPZ-induced demyelinated lesions — thereby promoting remyelin-
ation of  demyelinated axons.
Discussion
Here, we present evidence that local CNS production of  solTNF inhibits the onset of  remyelination and 
CNS repair in a CPZ model for MS by reducing the clearance of  myelin debris by phagocytic CNS macro-
phages. Therapeutic administration of  the selective solTNF inhibitor XPro1595 — which enters the intact 
CNS from the periphery in pharmacologically relevant concentrations — in CPZ-fed mice at the onset of  
histopathological changes did not halt the onset of  demyelination, axon damage, or gliosis triggered by the 
toxin, but promoted the remyelination of  demyelinated axons, resolved microgliosis, and halted progres-
sion of  axon damage, thereby completely preventing the decline in motor function that is associated with 
CPZ feeding. The beneficial effects of  solTNF blockade were associated with increased numbers of  OPC 
in demyelinating lesions and profound early remyelination of  demyelinated axons as a result of  improved 
clearance of  myelin debris by phagocytes in the presence of  XPro1595. These results identify a deleterious 
role for local brain solTNF in inhibiting myelin regeneration. They also show a beneficial role for tmTNF 
in remyelination, with the therapeutic effects of  XPro1595 being abolished in Tnf–/– mice and replicated in 
tmTnfΔ/Δ mice — findings consistent with previous reports that TNFR2, which efficiently transmits signals 
from tmTNF (32), is necessary for OLG proliferation and remyelination in this model (16).
It was important to exclude the possibility that XPro1595 treatment ameliorated demyelination in 
response to CPZ feeding. First, histochemical and immunochemical analyses showed that demyelin-
ation developed equally in the corpus callosum of  mice treated therapeutically or prophylactically with 
XPro1595 and vehicle. Second, the numbers of  apoptotic OLG were equal in the corpus callosum of  mice 
treated prophylactically with XPro1595 or vehicle at all time points of  CPZ administration, showing that 
solTNF does not contribute to OLG death in this model. Third, early demyelination developed similarly in 
Tnf–/– (CPZ5) and tmTNFΔ/Δ (CPZ3) mice as in vehicle-treated WT mice. In the CPZ model, OLG death 
occurs in two waves. A first early wave starts days after the initiation of  CPZ feeding. This is thought to 
result from combined metabolic stress (42) and local NO production (43), which directly sensitize OLG 
to apoptosis, as demonstrated by the sharply reduced expression of  myelin genes (26, 27) (Figure 4D and 
Supplemental Figure 1B), and the presence of  activated caspase 3 in OLG (41). Subsequently, accumulat-
ing inflammatory cells, predominantly activated microglia (36) but also infiltrating immune cells such as 
CXCR2-positive neutrophils (24), IL-17 signaling in CNS resident cells (44), and immune mediators such 
as chemokine (C-C motif) ligand 3/macrophage inflammatory protein-1α (Ccl3) (45), contribute to massive 
and CNPase-immunoreactive OLG with apoptotic nuclei/field, as detected by hematoxylin counterstaining of nuclei (×40) (curves, right axis). (C and D) 
Total numbers of Mac3-immunoreactive macrophages (Mφ)/field (×40) (C), and proportions of Mac3-immunoreactive macrophages containing PLP-
immunoreactive myelin/field (×40) (D), in the callosum of the same mice represented in A. (E) Proportions of mouse macrophage cells containing myelin 
basic protein–immunoreactive (MBP-immunoreactive) myelin assayed in the absence or presence of XPro1595. Statistical significance after comparisons 
between groups by two-way ANOVA with Bonferroni’s test (B, C, and D), or pairwise comparisons at each time point by Student’s t test (E), is shown. *P < 
0.05, **P < 0.01, ***P < 0.001, ##P < 0.01, ###P < 0.001. (B, D, and F) Asterisks denote statistical differences of each treatment group represented by bars 
with the same treatment group at the previous time point. Hash tags denote statistical differences of each treatment group represented on curves with 
the same treatment group at the previous time point. (A) Arrowheads show macrophages enlarged in insets (CPZ3), areas cleared of myelin debris (CPZ4), 
and new myelin (CPZ5).Circles show values for individual mice (B–E).
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OLG apoptosis by 4 weeks of  dietary CPZ (Figure 7B) and lead to demyelination in the corpus callosum. 
The specific molecular triggers of  OLG apoptosis in this model, however, remain to be identified, and as 
shown here, do not include TNF.
TNF and TNFR2 both promote CNS remyelination and repair in the EAE and CPZ models of  CNS 
demyelination. In the CPZ model, TNF and TNFR2 expression are upregulated in the brain during the 
demyelination process, and although the absence of  TNF in mice does not prevent demyelination or 
microglia proliferation, it significantly delays remyelination in the corpus callosum that normally takes 
place within weeks after withdrawal of  CPZ (16). This report further shows that TNF and TNFR2 are both 
necessary for the efficient proliferation of  NG2-immunoreactive OPC and remyelination of  demyelinated 
axons in this model (16). Our finding here that the local production of  solTNF in the CNS during CPZ 
demyelination inhibits remyelination, therefore, at first appears paradoxical. However, the observation that 
solTNF inhibition in WT mice allowed profound remyelination at a very early time point (CPZ4), while 
CPZ was still in the diet, and that this effect was abolished in Tnf–/– mice, provides strong evidence that 
solTNF inhibits tmTNF-dependent remyelination and is therefore fully consistent with previous findings. 
Similarly, XPro1595 administration protects mice against EAE disease symptoms. This is associated with 
preservation of  myelin morphology, increased numbers of  NG2-positive OPC and remyelinating axons, 
and neuroprotection (19, 46). tmTNF signals efficiently through TNFR2, and the recent finding that a 
human TNFR2 transgene is predominantly expressed on OPC rather than on differentiated OLG in prima-
ry OLG cultures isolated from mice — and that activation of  this receptor protects OPC against oxidative 
stress (47) — provides evidence that tmTNF might signal directly through TNFR2 on OLG lineage cells to 
mediate remyelination. Alternatively, tmTNF might signal indirectly through TNFR2 expressed on CNS 
macrophages in mice and patients with MS (19) to mediate remyelination. A requirement for OLG-specific 
TNFR2 expression for mediating remyelination following CNS demyelination was recently demonstrated 
in vivo in the EAE model (20). Taken together, the available data support that solTNF and TNFR1 inhibit 
remyelination, that tmTNF and TNFR2 promote OPC proliferation and remyelination, and that selective 
inhibition of  solTNF (and TNFR1) unmasks the full remyelinating potential of  tmTNF (and TNFR2).
The cellular mechanism underlying the inhibitory effect of  solTNF on remyelination does not appear 
to involve alteration of  OLG apoptosis or OPC proliferation, differentiation, or recruitment in response to 
CPZ-induced demyelination. While OPC responses to demyelination were increased in XPro1595-treated 
mice, this could not be explained by an increase in OPC proliferation in vivo, or of  OPC differentiation 
in vitro. On the other hand, our in vivo and in vitro data clearly show a role for solTNF in inhibiting the 
beneficial activity of  phagocytic CNS macrophages (microglia) in clearing myelin debris. solTNF is classi-
cally associated with chronically activated proinflammatory microglia and tissue damage in the CNS (17). 
Accordingly, XPro1595 treatment ameliorates microgliosis and primary pathology in a range of  experi-
mental models, including EAE (19, 46), cerebral ischemia (48), and Parkinson’s disease (49), and here 
resolved microgliosis in demyelinated lesions — findings that are all consistent with a role for solTNF in 
driving CNS inflammation. Interestingly, XPro1595-treated naive mice showed increased brain expression 
of  Chil3, which encodes a protein associated with host defense (37) and is used as a marker for beneficial 
alternatively activated macrophages. Previous work also shows that XPro1595 treatment induces a tran-
sient activation of  immune genes in the spinal cord at the onset of  EAE, in parallel to having protective 
effects on OLG and neuronal gene expression (50). Here, although XPro1595 treatment did not alter the 
numbers of  Mac3-positive macrophages in early demyelinating lesions, it increased the numbers and size 
of  macrophages containing myelin degradation products and facilitated the clearance of  myelin debris 
and remyelination in corpus callosum lesions. It also enhanced myelin phagocytosis by macrophages in 
vitro. Macrophages are known to be important for the remyelination response to demyelination. They are 
necessary for early stages of  remyelination and for the recruitment of  PDGFRα-immunoreactive OPC 
in a lysolecithin-induced demyelination model (refs. 12, 51). Macrophages are the main cell type respon-
sible for phagocytotic clearance of  myelin debris (52, 53), which contains inhibitors of  remyelination and, 
in turn, inhibits OPC differentiation in vitro (54) and in vivo (13). Studies in MS lesions provided ear-
ly evidence that different macrophages might be associated with different types of  MS lesions (55, 56). 
Thus, macrophages in active demyelinating lesions mainly express acute-stage inflammation markers and 
contain myelin-immunoreactive debris, while macrophages in remyelinating lesions are lipid-laden, often 
PAS-positive foamy cells that contain myelin breakdown products (55, 56), similar to those seen in the 
XPro1595-treated lesions. Although we were not able to distinguish between microglia and blood-derived 
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macrophages in this study, since both cell types can give rise to macrophages in the CNS, the finding that 
etanercept — which inhibits solTNF and tmTNF in the periphery — did not alter demyelination or remy-
elination strongly suggests that XPro1595 exerts its beneficial effects via CNS microglia. In support of  
this, recent studies in a model of  spinal cord injury show that TNF plays a critical role in maintaining the 
proinflammatory phenotype of  microglia/macrophages and inhibits a switch toward an antiinflammatory 
prorepair phenotype in the spinal cord following injury (57, 58).
Our data provide evidence that local production of  solTNF in the brain in a mouse model for demy-
elination and remyelination not only promotes the proinflammatory function of  microglia during demy-
elination, but also inhibits the beneficial function of  phagocytic CNS macrophages (microglia) in clearing 
myelin debris and permitting remyelination, a process mediated at least in part by tmTNF. Our results also 
suggest that selective inhibition of  solTNF by CNS-penetrating molecules such as XPro1595 represents a 
promising therapeutic approach for promoting remyelination and neuroprotection in diseases such as MS.
Methods
Mice. B6 mice were used for CPZ-induced demyelination. Tnf–/– mice (59) were backcrossed for at least 12 
generations onto the B6 background. tmTnfΔ/Δ mice (donated by Bernard Ryffel, University of  Orleans and 
CNRS, INEM, Molecular Immunology, Orleans, France) were generated directly onto the B6 background 
(33). Non-transgenic littermates were used as controls in all experiments. Mice were maintained under spe-
cific pathogen-free conditions in the experimental animal unit of  the Hellenic Pasteur Institute.
CPZ model of  demyelination and remyelination. Eight- to 10-week-old male WT, Tnf–/–, or tmTnfΔ/Δ mice 
were fed ad libitum with 0.2% w/w CPZ (Sigma-Aldrich; catalog C9012) in powdered standard mouse 
chow as described (21). Consistent with this model, we measured hallmark clinical features of  disease in 
the corpus callosum of  CPZ-treated WT mice at the end of  CPZ3 (microgliosis, astrocytosis, OPC pro-
liferation, and demyelination), CPZ5 (maximal demyelination, decline in motor performance), CPZ6+1 
(measurable remyelination), and CPZ6+4 (almost-complete remyelination).
Treatments with TNF inhibitors. CPZ-fed and naive control mice were treated with twice-weekly s.c. 
injections of  XPro1595 (10 mg/kg; Xencor) (18), etanercept (10 mg/kg; Amgen) (30), or saline vehicle. 
Experiments corresponding to Figures 1–6 were performed in mice treated using a therapeutic protocol, in 
which injections started at the end of  CPZ2, at the onset of  demyelination (21). In one set of  experiments 
(Figure 7), to test the effect of  TNF inhibitors on OLG apoptosis at different time points of  CPZ feeding, 
mice were treated prophylactically, with injections starting 2.5 weeks before CPZ feeding.
Rotarod test. Mice were tested for overall balance, motor coordination, and motor learning using a 
rotarod apparatus (ENV-575M, Med Associates Inc.), as described (40). Briefly, mice were placed on the 
rotating cylinder at an accelerating speed of  4–40 rpm and trained for 3 sessions per day for 3 consecutive 
days (days 11, 12, and 13 of  CPZ feeding), prior to the first test on day 14 (CPZ2), and tested once weekly 
from then on. The times mice remained on the cylinder were recorded.
Histology and IHC. Mice were transcardially perfused with ice-cold 4% paraformaldehyde in PBS under 
deep anaesthesia. Brains were removed, post-fixed in the same fixative overnight at 4°C, embedded in par-
affin or equilibrated in 15% sucrose, and snap frozen for cryostat sectioning. For histology and IHC, serial 
coronal paraffin sections (3–5 μΜ) were cut through the corpus callosum corresponding to Sidman sections 
295–305, and comparative analyses were made in the midline corpus callosum (area annotated in Fig-
ure 2A, vehicle-treated CPZ0 sample). Sections were stained with LFB for demyelination, and Biel silver 
impregnation for axonal damage according to standard procedures (60). IHC was performed as described 
(60) using the primary antibodies mouse anti-2’, 3’-cyclic nucleotide 3’-phosphodiesterase (CNPase) mAb 
(1/500; clone SMI-91; Covance), mouse SMI 32 mAb (1/1,000; clone SMI-32; Covance), rabbit anti–ion-
ized calcium-binding adaptor molecule 1 (Iba1) (1/500; Wako chemicals; catalog 019-19741), rabbit anti-
GFAP (1/300; Dako; catalog Z0334), rabbit anti–platelet-derived growth factor receptor alpha (PDGFRα) 
(1/150; donated by W. Stallcup, Sanford Burnham Prebys Institute, La Jolla, California, USA); followed 
by biotinylated secondary Abs, horseradish peroxidase-labeled avidin-biotin complex, and visualized using 
DAB (all from Vector Laboratories). Double immunostaining for proteolipid protein (PLP) and Mac3 was 
performed based on previous methods (60) using mouse anti-PLP (1/1,000; clone plpc1; Serotec), detec-
tion by alkaline phosphatase-conjugated anti–mouse secondary Ab (1/200; Jackson ImmunoResearch; 
catalog 115-056-068), and visualization by fast blue (blue reaction product), followed by antigen retrieval 
in 10 mM EDTA buffer (pH 8.5) for 1 hour at 95°C–100°C in a household food steamer, incubation with 
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rat anti-Mac3 mAb (1/200; clone M3/84; Serotec), and detection by biotinylated anti-rat Ab (1:500; Jack-
son ImmunoResearch; catalog 112-005-003), followed by avidin-peroxidase and visualization by 3-amino-
9-ethylcarbazole (red reaction product). Double immunofluorescence staining for proliferating OPC was 
performed using a mixture of  rabbit anti-PDGFRα (as above) and mouse anti-Ki67 mAb (1/50; clone B56; 
BD Biosciences), followed by a mixture of  AlexaFluor 568 anti-rabbit IgG (1/500; Molecular Probes; cata-
log A11011) and AlexaFluor 488 anti-mouse IgG (1/500; Molecular Probes; catalog A11001) secondary 
antibodies. Nuclei were counterstained with DAPI (1/1,000; Invitrogen; catalog D1306).
Histology quantification. Tissue sections were viewed with an Olympus BX-50 microscope and images 
captured with an Olympus DP71 microscope digital camera using cell^A imaging software (Soft Imaging 
System GmbH). Quantitative histopathological analysis was performed using Image J software. Demy-
elination was measured as loss of  LFB staining in coronal sections of  whole corpus callosum using a 
semiquantitative method, as described (16), and loss of  CNPase immunostaining in the midline corpus 
callosum by densitometry (area was used for all midline measurements shown in Figure 2A, vehicle-treated 
CPZ0 mouse). Axonal damage was measured as area covered by SMI 32 immunostaining in the midline 
corpus callosum. Microglia and OPC responses were measured as the areas covered by Iba1 and PDGFRα 
immunoreactivity, respectively, and as the numbers of  positive cells by stereology (Iba1-immunoreactive 
cells/mm3) or cell counting (PDGFRα-immunoreactive cells/mm2) in the midline corpus callosum. Cor-
pus callosum volumes in treatment groups were measured as described (61) using 30 μM serial coronal 
Cresyl Violet–stained cryostat sections taken between Bregma –1.3 and–2.3 with cell^A imaging software.
Stereology. Iba1-immunoreactive microglia/macrophage density in the corpus callosum was estimated by an 
unbiased stereological quantification method utilizing the optical fractionator principle incorporated in Stereo 
Investigator v10.0 software (MicroBrightField Bioscience), using a light microscope (Leica, DMRA2) equipped 
with a motorized stage (MAC5000, Ludl Electronic Products Ltd.) and top-mounted camera (QImaging), as 
described (62). Briefly, every fifth coronal free-floating cryostat section (30 μM) taken through the corpus cal-
losum between Bregma –1.3 and –2.3 was immunostained for Iba1 and counterstained with Cresyl Violet, and 
Iba1-immunoreactive microglia in the whole defined callosum volume were counted.
Electron microscopy. Vehicle- and XPro1595-treated naive (CPZ0) and CPZ4 mice were perfused 
with 4% paraformaldehyde/2.5% glutaraldehyde and post-fixed in the same fixative, and 300 μM thick 
sagittal vibratome slices were prepared using a Leica VT1200S vibratome (Leica). The region of  interest 
was punched out, postfixed with 2% OsO4 (Science Services), and embedded in Epon (Serva). Ultrathin 
sections (50 nm) were collected onto copper grids (Gilder Grids Ltd.), coated with formvar (Plano), 
and stained with 4% aqueous uranyl acetate (SPI-Chem) and lead citrate (63). Electron micrographs 
of  cross-sectioned axons in the caudal corpus callosum were taken with a LEO EM912 omega elec-
tron microscope (Zeiss) using an on-axis 2k CCD camera (TRS). Fifteen random pictures (at 6,300×) 
were taken as multiple image assemblies from each mouse, and all fibers per picture were analyzed 
using Image J (NIH) software. Three mice per group per time point were analyzed. Data are expressed 
as g-ratios (axon area/myelinated axon area) for all myelinated axons measured in callosum of  each 
mouse in each group (1 × 103/mm2).
Total RNA isolation and quantitative PCR. Total RNA was extracted from whole brains using TRIzol 
reagent (Thermo Fisher Scientific; catalog 15596026) per manufacturer’s instructions. DNase-treated RNA 
samples were subjected to quantitative PCR (qPCR) using a QuantiFast SYBR Green RT-PCR kit (Qiagen; 
catalog 204154), per manufacturer’s instructions. All reactions were performed using a LightCycler (Roche 
Diagnostics) as described (64). Values were normalized using the respective values for Gusb, or Gapdh 
(for Arg1, Chil3, Il1β, and Nos2). Results were analyzed using LightCycler software version 3.5 (Roche 
Diagnostics). QuantiTect Primer Assays were used for Arg1 (Qiagen primer code; Mm_Arg1_1_SG), Ccl2 
(Mm_Ccl2_1_SG), Chil3 (Mm_Chil3_1_SG), Cxcl16 (Mm_Cxcl16_1_SG), Gapdh (Mm_Gapdh_3_SG), 
Gusb (Mm_Gusb_1_SG), Il1β (mM_Il1b_2_SG), Mbp (Mm_Mbp_1_SG), Nos2 (mM_LOC673161_1_SG), 
Olig2 (Mm_Olig2_1_SG), Snap25 (Mm_Snap25_2_SG), and Tnf (Mm_Tnf_1_SG).
Measurement of  human TNF in blood and tissues. Blood was collected by heart puncture from deeply 
anesthetized vehicle- and XPro1595-treated naive (CPZ0) and CPZ5 mice, and sera were collected and 
snap frozen. Mice were briefly perfused with ice-cold PBS, and brains were removed and snap frozen. 
Levels of  human TNF (XPro1595) were measured in sera and brain lysates using a human TNF V-PLEX 
immunoassay (Meso Scale Discovery). Levels of  human TNFR2 Fc fusion protein (etanercept) were mea-
sured in sera and brain lysates using a human TNFR2 V-PLEX immunoassay (Meso Scale Discovery).
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Mixed cortical neuron-glial cultures. Primary mixed cortical neuron-glial cultures containing OLG lin-
eage cells were prepared from fetal B6 mice at embryonic day 14 (E14), based on established protocols 
(65). Briefly, dissociated cortical cells were grown on poly-D-lysine–coated (Sigma-Aldrich; catalog P6407) 
coverslips in 48-well plates in high-glucose DMEM (Sigma-Aldrich; catalog D5671) supplemented with 
5% horse serum (Thermo Fisher Scientific; catalog 16050122) and 5% FBS (Thermo Fisher Scientific; 
catalog 10270106). After 7 days in vitro (DIV7), recombinant murine TNF (100 ng/ml) (R&D systems; 
catalog 410-MT-010), or XPro1595 (100 ng/ml), was added for 24 or 48 hours. Cells were fixed with 
2% paraformaldehyde in PBS and immunostained using a mixture of  rabbit anti–NG2 (1/100; donated 
by W. Stallcup, Sanford Burnham Prebys Institute, La Jolla, California, USA) and mouse anti-O4 (1/25; 
clone 81; Merck Millipore) antibodies, followed by a mixture of  AlexaFluor 568 anti–rabbit IgG (1/500; 
Molecular Probes; catalog A11011) and AlexaFluor 488 anti–mouse IgG (1/500; Molecular Probes; cata-
log A11001) secondary Abs. Nuclei were counterstained with DAPI (1/1,000; Invitrogen; catalog D1306). 
Cells were viewed with an Olympus Time-Lapse microscope (×40 objective), and 20 images per well, in 
at least three separate cultures per condition, were captured using cell^R imaging software (Soft Imaging 
System GmbH). Total numbers of  DAPI-stained nuclei, NG2-positive OPC, and O4-positive OLG per well 
were counted and expressed as proportions of  DAPI-stained cell nuclei.
Myelin phagocytosis assay. Myelin was isolated from B6 mice as described (66). RAW 264.7 macro-
phage cells were grown according to supplier’s instructions (ECACC; catalog ATL02001) and seeded at 
4 × 105 cells/well together with myelin at 5 μl/ well in 24-well plates. Cells were incubated without or 
with XPro1595 (100 ng/ml) for different lengths of  time (0–40 hours), washed, fixed with 2% parafor-
maldehyde in PBS for 20 min, immunostained using rabbit anti-MBP antibody (1/200; Dako; catalog 
A0623) followed by AlexaFluor 568 anti–rabbit IgG (1/500; Molecular Probes; catalog A11011), and 
counterstained with DAPI.
Statistics. Data in figures are presented as mean ± SEM and individual data points. All statistical analy-
ses were performed using Prism 6 (GraphPad). Statistical analyses to compare the mean values for multiple 
groups were performed using ordinary one-way or two-way ANOVA combined with a post-test as stated in 
figure legends. Pairwise comparisons between individual groups was performed using a 2-tailed unpaired t 
test. Values were accepted as significant at P ≤ 0.05.
Study approval. All experimental protocols were evaluated and approved by the Institutional Protocol 
Evaluation Committee in Athens, Greece, and the national Hellenic authorities, and conformed to Euro-
pean Union guidelines. Licenses were issued by the Official Hellenic Veterinary Authorities.
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